The overall safety profile
of POLIVY-R-CHP is similar to that
of R-CHOP and consistent with the
known risk of the individual study drugs1
Specialist views covering a range of POLARIX trial topics
Dr Hervé Tilly
University of Rouen, France
Prof. Christopher Flowers
MD, Anderson Cancer Center, University of Texas
Dr Franck Morschhauser
MD, PhD Professor of Hematology,
University of Lille
Dr Laurie H. Sehn
MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia
| POLIVY-R-CHP | R-CHOP | |
More patients received all planned doses of polatuzumab vedotin in the POLIVY-R-CHP arm vs vincristine in the R-CHOP arm1
| 91.7%
| 88.5%
|
Fewer patients received a dose reduction due to adverse events in the POLIVY-R-CHP arm1
| 9.2%
| 13.0%
|
In 'number of patients' (%)
POLIVY-R-CHP (N=435) | R-CHOP (N=438) | |
| Any-grade AEs | 426 (97.9) | 431 (98.4) |
| Grade 3-4 AEs | 251 (57.7) | 252 (57.5) |
| SAEs | 148 (34.0) | 134 (30.6) |
| Grade 5 AEs | 13 (3.0) | 10 (2.3) |
| AEs leading to treatment discontinuation | ||
| Any treatment | 27 (6.2) | 29 (6.6) |
| Polatuzumab vedotin/vincristine | 19 (4.4) | 22 (5.0) |
| AEs leading to dose reduction (any treatment) | 40 (9.2) | 57 (13.0) |
POLIVY-R-CHP (N=435) | R-CHOP (N=438) | |||
| Adverse Event* In ‘number of patients’ (%) | Any Grade | Grade 3 or 4‡ | Any Grade | Grade 3 or 4‡ |
|---|---|---|---|---|
| Peripheral neuropathy† | 230 (52.9) | 7 (1.6) | 236 (53.9) | 5 (1.1) |
| Nausea | 181 (41.6) | 5 (1.1) | 161 (36.8) | 2 (0.5) |
| Neutropenia | 134 (30.8) | 123 (28.3) | 143 (32.6) | 135 (30.8) |
| Diarrhoea | 134 (30.8) | 17 (3.9) | 88 (20.1) | 8 (1.8) |
| Anaemia | 125 (28.7) | 52 (12.0) | 114 (26.0) | 37 (8.4) |
POLIVY-R-CHP had fewer cases of peripheral neuropathy leading to discontinuations (0.2% vs R-CHOP: 0.9%)1
Of patients who experienced any grade peripheral neuropathy, a lower percentage had Grade ≥2 or higher events with POLIVY-R-CHP compared with R-CHOP (POLIVY-R-CHP: 13.8% vs R-CHOP: 16.7%)1
Rates of febrile neutropenia were higher with POLIVY-R-CHP vs R-CHOP (14.3% vs 8.0%), but this did not translate into greater overall rates of infection: Grade 3 or 4 infections were comparable (15.2% vs 12.6%, respectively)1
*Top 5 most common adverse events, defined as AEs of any grade that occurred in at least 12% of the patients in either treatment group.
†Peripheral neuropathy includes the following preferred terms from the system organ class of peripheral neuropathy: peripheral neuropathy, peripheral sensory neuropathy, paresthesia, hypoesthesia, polyneuropathy, peripheral motor neuropathy, dysesthesia, neuralgia, peripheral sensorimotor neuropathy, hypotonia, hyporeflexia, neuromyopathy, ear paresthesia, peroneal nerve palsy, and skin burning sensation.
‡The percentage of grade 5 adverse events reported in POLIVY-R-CHP and R-CHOP, respectively: any grade 5 AE (3, 2.3), pneumonia (0.9,0.7) unexplained death (0.9,0.2), sepsis or septic shock (0.2,0.7), acute kidney injury (0.2,0), cardiac death (0.2,0), intestinal perforation (0.2,0), respiratory failure (0.2,0), multiple organ dysfunction syndrome (0,0.2), complete atrioventricular block (0,0.2), injury (0,0.2).1
?ts=1776172259585&$transparent.png$&dpr=off)
Interested in getting your patients started with POLIVY?
?ts=1776112631693&$transparent.png$&dpr=off)
AE=adverse event; N=size of population; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.
References:
© 2025 F. Hoffmann-La Roche Ltd. January 2025 M-XX-00010577
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
